Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 13;15(5):1165.
doi: 10.3390/v15051165.

Targeting CMV Reactivation to Optimize Care for Critically Ill COVID-19 Patients: A Review on the Therapeutic Potential of Antiviral Treatment

Georgios Schinas  1 , Vasiliki Moustaka  2 , Eleni Polyzou  1   3 , Maria Panagiota Almyroudi  4 , George Dimopoulos  5 , Karolina Akinosoglou  1   3
Affiliations
Review

Targeting CMV Reactivation to Optimize Care for Critically Ill COVID-19 Patients: A Review on the Therapeutic Potential of Antiviral Treatment

Georgios Schinas et al. Viruses. .

Abstract

Cytomegalovirus (CMV) reactivation has been linked to adverse clinical outcomes in critically ill patients, with emerging evidence suggesting a potential connection with severe COVID-19. Mechanisms driving this association may include primary lung injury, amplification of systemic inflammation, and secondary immunosuppression. Diagnostic challenges in detecting and assessing CMV reactivation necessitate a comprehensive approach to improve accuracy and inform treatment decisions. Currently, there is limited evidence on the efficacy and safety of CMV pharmacotherapy in critically ill COVID-19 patients. Although insights from non-COVID-19 critical illness studies suggest a potential role for antiviral treatment or prophylaxis, the risks and benefits must be carefully balanced in this vulnerable patient population. Understanding the pathophysiological role of CMV in the context of COVID-19 and exploring the advantages of antiviral treatment are crucial for optimizing care in critically ill patients. This review provides a comprehensive synthesis of available evidence, emphasizing the need for additional investigation to establish the role of CMV treatment or prophylaxis in the management of severe COVID-19 and to develop a framework for future research on this topic.

Keywords: CMV; COVID-19; SARS-CoV-2; antiviral agents; critically ill; cytomegalovirus infections; intensive care units.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA Flowchart for the selection process of studies included in this review.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Zuhair M., Smit G.S.A., Wallis G., Jabbar F., Smith C., Devleesschauwer B., Griffiths P. Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis. Rev. Med. Virol. 2019;29:e2034. doi: 10.1002/rmv.2034. - DOI - PubMed
    1. Griffiths P., Baraniak I., Reeves M. The pathogenesis of human cytomegalovirus. J. Pathol. 2015;235:288–297. doi: 10.1002/path.4437. - DOI - PubMed
    1. Boeckh M., Geballe A.P. Cytomegalovirus: Pathogen, paradigm, and puzzle. J. Clin. Investig. 2011;121:1673–1680. doi: 10.1172/JCI45449. - DOI - PMC - PubMed
    1. Schildermans J., De Vlieger G. Cytomegalovirus: A Troll in the ICU? Overview of the Literature and Perspectives for the Future. Front. Med. 2020;7:188. doi: 10.3389/fmed.2020.00188. - DOI - PMC - PubMed
    1. Söderberg-Nauclér C.J.J.o.I.M. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J. Intern. Med. 2006;259:219–246. doi: 10.1111/j.1365-2796.2006.01618.x. - DOI - PubMed

Substances